
|Videos|February 16, 2023
Case 3: Faricimab in a neovascular nAMD patient with persistent fluid
Advertisement
Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.
Sponsored by Roche
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The gene therapy shift: A closer look at the science powering next-generation retinal treatments
2
Understanding fluid fluctuation in retinal disorders
3
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
4
Q&A: Veeral Sheth, MD, MBA, on personalized, imaging-centered geographic atrophy care
5












































